Allergan, Inc.

Eldon Q Farnes

Chin-Ming Chang

Rhett M Schiffman

Richard S Graham

Mayssa Attar

Devin F Welty

James Nienyuan Chang

Orest Olejnik

The present invention provides an aqueous ophthalmic solution with an effective amount of ketorolac and carboxymethyl cellulose in an aqueous solution which provides increased visual acuity and wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Ketorolac tromethamine compositions for treating or preventing ocular pain

The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Ketorolac tromethamine compositions for treating ocular pain

The present invention is directed to an ophthalmic formulation which comprises a therapeutically effective amount of ethyl 4-(8-chloro-5,6-dihydro-11-benzo&lsqb;5,6&rsqb;cyclohepta&lsqb;1,2-b&rsqb;pyridin-11-ylidene)-1-piperidinecarboxylate, known as loratadine, a fatty acid ester, and a surfactant, which has been found to be useful in treating ocular allergies, especially allergic conjunctivitis, and related conditions.

Ophthalmic compositions containing loratadine

Growing community of inventors

Laguna Beach, CA, United States of America

Eldon Q Farnes